Please provide your email address to receive an email when new articles are posted on . Most people with alopecia are good candidates for JAK inhibitor therapy with proper counseling and monitoring.

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting the prospects of a candidate designed to avoid the adverse events caused by ...

NEW YORK — Potential upcoming approvals of JAK inhibitors for hidradenitis suppurativa (HS) and vitiligo suggest these drugs are becoming one of the most versatile therapies in dermatology, and their ...

For much of the 2025 season, Jak Crawford has been considered the next American hopeful for Formula One. The last American to compete in the pinnacle of motorsport was Logan Sargeant, who raced for ...

Maddie Fisher is a writer, journalist and game developer. She was born and raised on the east coast, having started working in games journalism over fifteen years ago. She tends to enjoy musical ...

Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...

Jake brings two decades of experience with him, having covered major industry events, breaking news, one-on-one interviews, and more. When he's not playing World of Warcraft, he's usually on the hunt ...

Moises Mendez II is an associate editor at Out Magazine based in Brooklyn, New York. He covers internet culture and entertainment, including television, movies, music, and more. Before joining Out, he ...

For Jak Malone, being a dedicated fan pays off. “I knew that some of my favorite writers were making a musical,” says the 31-year-old actor, nominated for a Tony Award for Best Actor in a Featured ...

GameSpot may get a commission from retail offers. This week's Triple- Initiative covered a wide range of genres, but for anyone looking for a retro-inspired platformer, then Duskfade was likely the ...

Ruxolitinib cream shows comparable efficacy to systemic therapies in reducing disease severity in moderate atopic dermatitis, with significant BSA reduction over 7.4 months. Abrocitinib demonstrates ...